Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 33 studies | 28% ± 8% | |
macrophage | 27 studies | 30% ± 14% | |
oligodendrocyte | 14 studies | 39% ± 17% | |
monocyte | 12 studies | 23% ± 7% | |
microglial cell | 12 studies | 36% ± 14% | |
myeloid cell | 10 studies | 41% ± 13% | |
endothelial cell of artery | 10 studies | 24% ± 7% | |
dendritic cell | 9 studies | 31% ± 11% | |
type II pneumocyte | 9 studies | 42% ± 14% | |
glutamatergic neuron | 9 studies | 49% ± 22% | |
epithelial cell | 9 studies | 27% ± 10% | |
fibroblast | 9 studies | 25% ± 5% | |
endothelial cell of vascular tree | 9 studies | 32% ± 11% | |
classical monocyte | 8 studies | 22% ± 8% | |
non-classical monocyte | 8 studies | 20% ± 5% | |
conventional dendritic cell | 8 studies | 23% ± 7% | |
adipocyte | 8 studies | 37% ± 11% | |
GABAergic neuron | 7 studies | 42% ± 19% | |
pericyte | 7 studies | 24% ± 4% | |
vein endothelial cell | 7 studies | 31% ± 16% | |
oligodendrocyte precursor cell | 7 studies | 28% ± 9% | |
mononuclear phagocyte | 6 studies | 31% ± 13% | |
neuron | 6 studies | 30% ± 13% | |
mast cell | 6 studies | 34% ± 17% | |
endothelial cell of lymphatic vessel | 6 studies | 29% ± 9% | |
capillary endothelial cell | 5 studies | 23% ± 5% | |
smooth muscle cell | 5 studies | 21% ± 6% | |
cardiac muscle cell | 5 studies | 54% ± 12% | |
astrocyte | 5 studies | 30% ± 10% | |
club cell | 5 studies | 39% ± 17% | |
pancreatic A cell | 4 studies | 32% ± 8% | |
kidney loop of Henle epithelial cell | 4 studies | 22% ± 5% | |
ciliated cell | 4 studies | 32% ± 11% | |
hepatocyte | 4 studies | 54% ± 23% | |
luminal cell of prostate epithelium | 4 studies | 19% ± 2% | |
goblet cell | 4 studies | 22% ± 4% | |
leukocyte | 4 studies | 28% ± 6% | |
interneuron | 4 studies | 46% ± 21% | |
retinal cone cell | 3 studies | 21% ± 2% | |
enteroendocrine cell | 3 studies | 24% ± 5% | |
alveolar macrophage | 3 studies | 39% ± 13% | |
granule cell | 3 studies | 27% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 3746.96 | 89 / 89 | 100% | 28.71 | 898 / 901 |
prostate | 100% | 1840.99 | 244 / 245 | 99% | 26.26 | 499 / 502 |
brain | 99% | 1963.23 | 2626 / 2642 | 100% | 14.36 | 702 / 705 |
esophagus | 100% | 2530.35 | 1438 / 1445 | 98% | 16.22 | 179 / 183 |
intestine | 100% | 2522.98 | 966 / 966 | 97% | 12.69 | 512 / 527 |
lung | 100% | 3611.21 | 578 / 578 | 97% | 16.70 | 1120 / 1155 |
skin | 100% | 2036.63 | 1806 / 1809 | 97% | 20.74 | 458 / 472 |
stomach | 100% | 2227.56 | 359 / 359 | 97% | 14.09 | 277 / 286 |
pancreas | 99% | 1499.14 | 325 / 328 | 97% | 15.43 | 173 / 178 |
thymus | 100% | 2300.47 | 653 / 653 | 96% | 10.77 | 580 / 605 |
breast | 100% | 2717.52 | 458 / 459 | 94% | 11.28 | 1051 / 1118 |
adrenal gland | 99% | 1534.56 | 256 / 258 | 92% | 11.61 | 211 / 230 |
bladder | 100% | 1932.67 | 21 / 21 | 87% | 8.51 | 440 / 504 |
uterus | 100% | 1782.21 | 170 / 170 | 86% | 8.31 | 396 / 459 |
liver | 100% | 3211.32 | 226 / 226 | 85% | 11.19 | 346 / 406 |
ovary | 99% | 1337.86 | 179 / 180 | 46% | 2.37 | 198 / 430 |
adipose | 100% | 3581.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3899.52 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1842.80 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 99% | 3250.15 | 854 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 1777.93 | 793 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 21.96 | 78 / 80 |
tonsil | 0% | 0 | 0 / 0 | 87% | 7.02 | 39 / 45 |
lymph node | 0% | 0 | 0 / 0 | 62% | 4.86 | 18 / 29 |
peripheral blood | 39% | 843.76 | 360 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0006468 | Biological process | protein phosphorylation |
GO_1904263 | Biological process | positive regulation of TORC1 signaling |
GO_0001932 | Biological process | regulation of protein phosphorylation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0008630 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0031334 | Biological process | positive regulation of protein-containing complex assembly |
GO_1990877 | Cellular component | FNIP-folliculin RagC/D GAP |
GO_0005737 | Cellular component | cytoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0034451 | Cellular component | centriolar satellite |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0042030 | Molecular function | ATPase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FNIP2 |
Protein name | Folliculin interacting protein 2 Folliculin-interacting protein 2 (FNIP1-like protein) (O6-methylguanine-induced apoptosis 1 protein) |
Synonyms | FNIPL KIAA1450 MAPO1 |
Description | FUNCTION: Binding partner of the GTPase-activating protein FLCN: involved in the cellular response to amino acid availability by regulating the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 . Required to promote FLCN recruitment to lysosomes and interaction with Rag GTPases, leading to activation of the non-canonical mTORC1 signaling (By similarity). In low-amino acid conditions, component of the lysosomal folliculin complex (LFC) on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, thereby inactivating mTORC1 and promoting nuclear translocation of TFEB and TFE3 . Upon amino acid restimulation, disassembly of the LFC complex liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent inactivation of TFEB and TFE3 . Together with FLCN, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy . In addition to its role in mTORC1 signaling, also acts as a co-chaperone of HSP90AA1/Hsp90: inhibits the ATPase activity of HSP90AA1/Hsp90, leading to activate both kinase and non-kinase client proteins of HSP90AA1/Hsp90 . Acts as a scaffold to load client protein FLCN onto HSP90AA1/Hsp90 . Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins . May play a role in the signal transduction pathway of apoptosis induced by O6-methylguanine-mispaired lesions (By similarity). . |
Accessions | H0Y8F3 D6RFH5 ENST00000512986.5 ENST00000264433.11 [Q9P278-1] ENST00000504715.1 Q9P278 |